TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02428218
Drug: dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enteric-coated microtablets
Study: NCT00333281
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00215722
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00536081
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg s.c. 24-36 h post-chemotherapy
Study: NCT02396953
Drug: Lanreotide PRF
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00725036
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01562587
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single bolus dose is administered. Injected intravenously
Study: NCT01562587
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
Study: NCT00003698
Drug: fosbretabulin disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00206505
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01520077
Drug: vytorin
Normalized name: Vytorin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
Study: NCT01928407
Drug: DARUNAVIR
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
Study: NCT01928407
Drug: ATAZANAVIR
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
Study: NCT02716688
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.
Study: NCT01810913
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01810913
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03320642
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib administered orally once daily at the protocol-defined dose.
Study: NCT01810913
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02843126
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)
Study: NCT04512430
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~* No premedication administered for atezolizumab specifically is permitted~* Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~* If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles \> 2 at the discretion of the treating physician.~* If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes.
Study: NCT04585737
Drug: Dolutegravir / Lamivudine Pill
Normalized name: dolutegravir / lamiVUDine Pill
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental
Study: NCT04585737
Drug: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
Normalized name: bictegravir / emtricitabine / tenofovir alafenamide Pill
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active comparator
Study: NCT04512430
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
Study: NCT04512430
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center
Study: NCT04512430
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo\[2,3 d\]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center
Study: NCT01591668
Drug: Multiple Ascending Dose Cohorts GS-9620
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Study: NCT00331838
Drug: Semuloparin sodium
Normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mL solution in Type I amber glass vials~Subcutaneous injection
Study: NCT00331838
Drug: Placebo (for Enoxaparin sodium)
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study: NCT00331838
Drug: Enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection
Study: NCT00902226
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible-dosed (5 to 20 mg Oral Tablets Daily)
Study: NCT01049984
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mg tablet daily for 18 weeks
Study: NCT01974440
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
Study: NCT01974440
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
Study: NCT01974440
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
Study: NCT01974440
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
Study: NCT02753764
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral prednisone 20 mg bid for one week
Study: NCT01974440
Drug: PCI-32765 (Ibrutinib)
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
Study: NCT00331838
Drug: Placebo (for Semuloparin sodium)
Normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study: NCT00254553
Drug: Testim 1% (testosterone gel)
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testim_ 100 mg: two tubes of 50 mg of Testim_per day
Study: NCT03925662
Drug: Folfox with avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Folfox with avastin only
Study: NCT03925662
Drug: Mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folfox with avastin with mebendazole
Study: NCT03214250
Drug: APX005M
Normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer intravenously once every 28-day Cycle
Study: NCT03214250
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer intravenously twice every 28-day cycle
Study: NCT03214250
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer intravenously on 3 times every 28-day cycle
Study: NCT03214250
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administer intravenously 3 times every 28-day cycle
Study: NCT00508534
Drug: SB-751689
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00727129
Drug: Divigel
Normalized name: Divigel
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02115282
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02115282
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02115282
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04189341
Drug: Erector spinae plane block (Group E)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study: NCT02115282
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given SC
Study: NCT04189341
Drug: Modified-thoracolumbar interfascial plane block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study: NCT00523549
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 160 mg or 320 mg tablets once a day
Study: NCT00523549
Drug: amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg or 10 mg tablets once a day
Study: NCT01579110
Drug: levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
Study: NCT01207752
Drug: Systane Balance
Normalized name: Systane Balance
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artificial tear emulsion drop
Study: NCT05598281
Drug: AMG 510
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT01579110
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
Study: NCT01219777
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
Study: NCT01219777
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
Study: NCT01219777
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
Study: NCT03084939
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
Study: NCT05598281
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT00613613
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 145mg tablets once daily for 4 weeks
Study: NCT00087477
Drug: Pivanex
Normalized name: Pivanex
DrugBank: AN-9 (DB05103)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00162552
Drug: pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with severe cirrhosis treated with Pentoxifylline
Study: NCT00404508
Drug: Hydralazine and magnesium valproate
Normalized name: magnesium valproate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02414555
Drug: fluid bolus
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02414555
Drug: Elo-Mel Isoton (balanced acetat-based infusate)
Normalized name: Mel
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00629551
Drug: saredutant (SR48968)
Normalized name: Saredutant
DrugBank: Saredutant (DB06660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration,capsules
Study: NCT03671330
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
Study: NCT03671330
Drug: NSAI: Letrozole or Anastrazole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole.
Study: NCT00629551
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration, capsules
Study: NCT00557336
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03671330
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
Study: NCT03671330
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
Study: NCT02476058
Drug: JNJ-42847922
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Study: NCT02476058
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Study: NCT03756922
Drug: FDL169
Normalized name: FDL169
DrugBank: FDL169 (DB16878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFTR corrector
Study: NCT03682380
Drug: Seltorexant High Dose
Normalized name: high-density polyethylene
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
Study: NCT03682380
Drug: Seltorexant Low Dose
Normalized name: ethinyl estradiol
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
Study: NCT02252172
Drug: Daratumumab IV
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
Study: NCT02252172
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
Study: NCT02252172
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg orally or intravenously once in a week.
Study: NCT02252172
Drug: Daratumumab SC
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
Study: NCT03693391
Drug: JNJ-64140284
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
Study: NCT01744756
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One subconjunctival aplication of Bevacizumabe 0,5ml
Study: NCT00335374
Drug: Pardoprunox
Normalized name: Pardoprunox
DrugBank: Pardoprunox (DB12061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 -42 mg
Study: NCT01476124
Drug: morphine Placebo
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine Placebo
Study: NCT01476124
Drug: GEn 600 mg
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin enacarbil 600 mg
Study: NCT01476124
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine extended release 60 mg
Study: NCT01381458
Drug: ACs
Normalized name: EACS
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tiotropium alone, ipratropium alone, or in combination with albuterol
Study: NCT00402584
Drug: sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04300322
Drug: Vaginal Progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
Study: NCT00646711
Drug: Depakote ER
Normalized name: Depakote ER
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
Study: NCT01717170
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (4 mg/kg or 8 mg/kg)
Study: NCT02511340
Drug: Flumatinib mesylate tablet 600 mg qd
Normalized name: eprosartan
DrugBank: Flumatinib (DB11904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients